表紙
市場調査レポート

ImmunoBiology Ltd.の製品パイプライン分析

ImmunoBiology Limited - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 317880
出版日 ページ情報 英文 24 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
ImmunoBiology Ltd.の製品パイプライン分析 ImmunoBiology Limited - Product Pipeline Review - 2015
出版日: 2015年07月29日 ページ情報: 英文 24 Pages
概要

ImmunoBiology Ltd.は英国に本社をおくバイオテクノロジー企業で、髄膜炎、肺炎、結核、 クロストリジウム-ディフィシル、ヘリコバクター・ピロリ、インフルエンザ、C型肝炎などを適応とするワクチンの開発と販売を行っています。

当レポートでは、ImmunoBiology Ltd.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

ImmunoBiology Ltd.の基本情報

  • ImmunoBiology Ltd.の概要
  • 主要情報
  • 企業情報

ImmunoBiology Ltd.:R&Dの概要

  • 主な治療範囲

ImmunoBiology Ltd.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

ImmunoBiology Ltd.:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

ImmunoBiology Ltd.:薬剤プロファイル

  • FluBioVax
  • MenBioVax
  • PnuBioVax
  • T-BioVax
  • clostridium difficile vaccine
  • helicobacter pylori vaccine
  • HepBioVax

ImmunoBiology Ltd.:パイプライン分析

  • 標的別
  • 分子タイプ別

ImmunoBiology Ltd.:最新のパイプライン動向

ImmunoBiology Ltd.:本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07208CDB

Summary

Global Markets Direct's, 'ImmunoBiology Limited - Product Pipeline Review - 2015', provides an overview of the ImmunoBiology Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ImmunoBiology Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of ImmunoBiology Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ImmunoBiology Limited's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ImmunoBiology Limited's pipeline products

Reasons to buy

  • Evaluate ImmunoBiology Limited's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ImmunoBiology Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ImmunoBiology Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ImmunoBiology Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ImmunoBiology Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ImmunoBiology Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • ImmunoBiology Limited Snapshot
    • ImmunoBiology Limited Overview
    • Key Information
    • Key Facts
  • ImmunoBiology Limited - Research and Development Overview
    • Key Therapeutic Areas
  • ImmunoBiology Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • ImmunoBiology Limited - Pipeline Products Glance
    • ImmunoBiology Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • ImmunoBiology Limited - Drug Profiles
    • FluBioVax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MenBioVax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PnuBioVax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • T-BioVax
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Clostridium difficile vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • helicobacter pylori vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Hepatitis C Vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • ImmunoBiology Limited - Pipeline Analysis
    • ImmunoBiology Limited - Pipeline Products by Target
    • ImmunoBiology Limited - Pipeline Products by Molecule Type
  • ImmunoBiology Limited - Recent Pipeline Updates
  • ImmunoBiology Limited - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • ImmunoBiology Limited, Key Information
  • ImmunoBiology Limited, Key Facts
  • ImmunoBiology Limited - Pipeline by Indication, 2015
  • ImmunoBiology Limited - Pipeline by Stage of Development, 2015
  • ImmunoBiology Limited - Monotherapy Products in Pipeline, 2015
  • ImmunoBiology Limited - Preclinical, 2015
  • ImmunoBiology Limited - Discovery, 2015
  • ImmunoBiology Limited - Pipeline by Target, 2015
  • ImmunoBiology Limited - Pipeline by Molecule Type, 2015
  • ImmunoBiology Limited - Recent Pipeline Updates, 2015

List of Figures

  • ImmunoBiology Limited - Pipeline by Top 10 Indication, 2015
  • ImmunoBiology Limited - Pipeline by Stage of Development, 2015
  • ImmunoBiology Limited - Monotherapy Products in Pipeline, 2015
  • ImmunoBiology Limited - Pipeline by Top 10 Target, 2015
  • ImmunoBiology Limited - Pipeline by Top 10 Molecule Type, 2015
Back to Top